Scholars@Duke
Elise Arline Olsen

Elise Arline Olsen

Professor of Dermatology
Dermatology
Duke Box 3294, Durham, NC 27710
3346 Hospital South, Durham, NC

Selected Publications

ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.

Journal Article Transplant Cell Ther · November 2024 Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease; Sézary sy ... Full text Link to item Cite

Worldwide Clinical and Real-World Exposure to Baricitinib

Journal Article SKIN: Journal of Cutaneous Medicine · November 1, 2024 Introduction: Baricitinib (BARI), an oral selective JAK inhibitor, is approved in many geographies for adults with rheumatoid arthritis or alopecia areata and for patients as young as age 2 years with atopic dermatitis or juvenile idiopathic arthritis. It ... Full text Cite

Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations.

Journal Article J Am Acad Dermatol · June 2024 BACKGROUND: There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely. OBJECTIVE: To develop consensus statements regarding the use of various pharmacological therapies in tr ... Full text Link to item Cite

The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.

Journal Article JAMA Dermatol · March 1, 2024 IMPORTANCE: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. OBJECTIVE: To explore factors associated with AA severity beyond scalp hair loss, and to support t ... Full text Link to item Cite

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.

Journal Article JAMA Dermatol · September 1, 2022 IMPORTANCE: Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects. Topical synthetic hypericin ointment, 0.25%, activated with visible light i ... Full text Link to item Cite

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.

Journal Article Blood · August 4, 2022 The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most co ... Full text Link to item Cite

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · March 2022 Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunob ... Full text Link to item Cite

Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).

Journal Article Br J Dermatol · December 2021 BACKGROUND: Frontal fibrosing alopecia (FFA) has become one of the most common causes of cicatricial alopecia worldwide. However, there is a lack of clear aetiology and robust clinical trial evidence for the efficacy and safety of agents currently used for ... Full text Link to item Cite

The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata.

Journal Article J Am Acad Dermatol · June 2021 BACKGROUND: We previously reported the Alopecia Areata Consensus of Experts study, which presented results of an international expert opinion on treatments for alopecia areata. OBJECTIVE: To report the results of the Alopecia Areata Consensus of Experts in ... Full text Link to item Cite

A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).

Journal Article JAMA Dermatol · April 1, 2021 IMPORTANCE: A recent expert consensus exercise emphasized the importance of developing a global network of patient registries for alopecia areata to redress the paucity of comparable, real-world data regarding the effectiveness and safety of existing and e ... Full text Link to item Cite

Hair Loss

Chapter · January 1, 2021 Acute hair loss during chemotherapy for breast cancer is common and usually reversible, but occasionally this may become persistent after treatment is completed. Endocrine therapy, because of its effect on the synthesis of both androgens and estrogens and ... Full text Cite

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

Journal Article J Natl Compr Canc Netw · November 2, 2020 Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is ... Full text Link to item Cite

The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata.

Journal Article J Am Acad Dermatol · July 2020 BACKGROUND: A systematic review failed to identify any systemic therapy used in alopecia areata (AA) where use is supported by robust evidence from high-quality randomized controlled trials. OBJECTIVE: To produce an international consensus statement on the ... Full text Link to item Cite

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

Journal Article J Natl Compr Canc Netw · May 2020 Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effecti ... Full text Link to item Cite

Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.

Journal Article J Am Acad Dermatol · February 2020 BACKGROUND: There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemi ... Full text Link to item Cite

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.

Journal Article J Clin Endocrinol Metab · July 1, 2019 OBJECTIVE: To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form of hair loss in women that is characterized by the reduc ... Full text Link to item Cite

Focal atrichia: A diagnostic clue in female pattern hair loss.

Journal Article J Am Acad Dermatol · June 2019 BACKGROUND: Focal atrichia is a common clinical finding in female pattern hair loss, the specificity and histologic findings of which need further clarification. OBJECTIVE: To determine the frequency of focal atrichia in various types of hair loss and its ... Full text Link to item Cite

Objective outcome measures: Collecting meaningful data on alopecia areata.

Journal Article J Am Acad Dermatol · September 2018 BACKGROUND: Although alopecia areata is a common disorder, it has no US Food and Drug Administration-approved treatment and evidence-based therapeutic data are lacking. OBJECTIVE: To develop guidelines for the diagnosis, evaluation, assessment, response cr ... Full text Link to item Cite

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

Journal Article J Natl Compr Canc Netw · February 2018 Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract. Because extranodal NK/T-ce ... Full text Link to item Cite

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.

Journal Article Mod Pathol · May 2017 Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous lymphom ... Full text Link to item Cite

Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.

Journal Article J Drugs Dermatol · July 1, 2016 BACKGROUND: A once-daily minoxidil topical foam (MTF) has been developed to treat female pattern hair loss. OBJECTIVE: Determine noninferiority of once-daily 5% MTF versus twice-daily 2% minoxidil topical solution (MTS) based on the change from baseli ... Link to item Cite

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · May 2016 Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be ... Full text Link to item Cite

Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.

Journal Article J Am Acad Dermatol · January 2016 BACKGROUND: Ultraviolet light (UVL) is a long established treatment for mycosis fungoides (MF) and Sézary syndrome (SS), subtypes of cutaneous T-cell lymphoma (CTCL). Treatments have traditionally included broadband, narrowband ultraviolet B light (UVB) an ... Full text Link to item Cite

Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.

Journal Article Dermatol Clin · October 2015 Primary cutaneous lymphomas (PCLs) are an extremely heterogeneous group of non-Hodgkin lymphomas that manifest in the skin. Their diagnosis is complex and based on clinical lesion type and evaluation of findings on light microscopic examination, immunohist ... Full text Link to item Cite

Cutaneous Lymphoma.

Journal Article Dermatol Clin · October 2015 Full text Link to item Cite

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

Journal Article Ann Oncol · September 2014 BACKGROUND: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T and B cells, resulting in apoptosis. Forodesine has demonstrated impressive antitumor ... Full text Link to item Cite

Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research.

Journal Article Dermatol Clin · April 2014 Central centrifugal cicatricial alopecia is an inflammatory type of central scalp hair loss seen primarily in women of African descent. The prevalence is unknown, but may vary from 2.7% to 5.7% and increases with age. This review outlines the history and c ... Full text Link to item Cite

Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University.

Journal Article J Am Acad Dermatol · May 2013 BACKGROUND: Frontal fibrosing alopecia (FFA) is a type of scarring hair loss primarily observed in postmenopausal women and characterized by fronto-tempero-parietal hairline recession, perifollicular erythema, and loss of eyebrows. The incidence is unknown ... Full text Link to item Cite

Mycosis fungoides.

Journal Article Mayo Clin Proc · March 2013 Full text Link to item Cite

Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.

Journal Article Leuk Lymphoma · March 2013 This open-label phase III trial, a companion to an earlier placebo-controlled trial, evaluated safety and efficacy of denileukin diftitox (DD) in patients with cutaneous T-cell lymphoma (CTCL) who relapsed after responding to DD primary treatment in the ea ... Full text Link to item Cite

Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.

Journal Article Leuk Lymphoma · January 2013 In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cel ... Full text Link to item Cite

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Journal Article JAMA Dermatol · January 2013 OBJECTIVE: To evaluate the efficacy and safety of a novel mechlorethamine hydrochloride, 0.02%, gel in mycosis fungoides. DESIGN Randomized, controlled, observer-blinded, multicenter trial comparing mechlorethamine, 0.02%, gel with mechlorethamine, 0.02%, ... Full text Link to item Cite

Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

Journal Article J Am Acad Dermatol · November 2012 Dermatologic adverse events to cancer therapies have become more prevalent and may to lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has resulted in a new collaboration between oncologists and dermatologists, wh ... Full text Link to item Cite

Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas.

Journal Article Am J Surg Pathol · November 2012 We reviewed our multicenter experience with gamma-delta (γδ) T-cell lymphomas first presenting in the skin. Fifty-three subjects with a median age of 61 years (range, 25 to 91 y) were diagnosed with this disorder. The median duration of the skin lesions at ... Full text Link to item Cite

Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.

Journal Article J Am Acad Dermatol · September 2012 BACKGROUND: Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal scalp hair growth in subjects aged 18 to 41 years. OBJECTIVE: A secondary efficacy analysis was cond ... Full text Link to item Cite

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Journal Article Blood · October 13, 2011 Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphol ... Full text Link to item Cite

Untangling the hairy issue of iron deficiency: Making progress

Journal Article Journal of the American Academy of Dermatology · July 1, 2011 Full text Cite

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Journal Article J Clin Oncol · June 20, 2011 Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardizat ... Full text Link to item Cite

Hair Disorders

Journal Article · May 24, 2011 Full text Cite

An in-depth assessment of the impact of pruritus on health-related quality of life of patients with mycosis fungoides/sézary syndrome

Journal Article Journal of Supportive Oncology · May 1, 2011 To quantify pruritus and assess its impact on the quality of life of patients with mycosis fungoides (MF) and Sézary syndrome (SS), investigators at 2 centers conducted in-depth interviews of MF/SS patients aged ≥18 years who experienced pruritus associate ... Full text Cite

Central hair loss in African American women: incidence and potential risk factors.

Journal Article J Am Acad Dermatol · February 2011 BACKGROUND: Although central scalp hair loss is a common problem in African American women, data on etiology or incidence are limited. OBJECTIVE: We sought to determine the frequency of various patterns and degree of central scalp hair loss in African Amer ... Full text Link to item Cite

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

Journal Article J Am Acad Dermatol · February 2011 Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of ... Full text Link to item Cite

Treatment of chemotherapy-induced alopecia.

Journal Article Dermatol Ther · 2011 Chemotherapy-induced alopecia has been well documented as a cause of distress to patients undergoing cancer treatment. Despite the importance of hair loss to patients, however, patients often receive little more counseling than the advice to purchase a wig ... Full text Link to item Cite

Investigative guidelines for alopecia areata.

Journal Article Dermatol Ther · 2011 The reported efficacy of various treatments for alopecia is difficult to compare based on a general lack of consideration in case reports/series and clinical trials of the spontaneous regrowth or baseline prognostic factors seen in alopecia areata and a ge ... Full text Link to item Cite

Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups.

Journal Article J Am Acad Dermatol · December 2010 BACKGROUND: The literature suggests that iron deficiency (ID) may play a role in female pattern hair loss (FPHL) or in chronic telogen effluvium (CTE). OBJECTIVE: We sought to determine if ID is more common in women with FPHL and/or CTE than in control sub ... Full text Link to item Cite

The United States Cutaneous Lymphoma Consortium (USCLC).

Journal Article Clin Lymphoma Myeloma Leuk · September 2010 Full text Link to item Cite

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

Journal Article Support Care Cancer · April 2010 BACKGROUND: Accurate grading of dermatologic adverse events (AE) due to epidermal growth factor receptor (EGFR) inhibitors (EGFRIs) is necessary for drug toxicity determinations, interagent comparisons, and supportive care trials. The most widely used seve ... Full text Link to item Cite

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Journal Article Clin Lymphoma Myeloma · December 2009 INTRODUCTION: Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, pe ... Full text Link to item Cite

Leukonychia related to vorinostat.

Journal Article Arch Dermatol · November 2009 Full text Link to item Cite

Forodesine

Journal Article Haematologica Meeting Reports · September 9, 2009 Cite

Female pattern hair loss

Journal Article · December 1, 2008 • Decrease in hair density in the central (vertex, mid and frontal) scalp, bitemporal and parietal regions in women. • Miniaturization of affected hairs. • Two ages of onset: early (post-puberty to third decade) and late (age 40+ years). • Signs of hyperan ... Full text Cite

SUMMARY OF THE CLINICAL BENEFIT OF VORINOSTAT IN RELAPSED/REFRACTORY CTCL

Journal Article HAEMATOLOGICA-THE HEMATOLOGY JOURNAL · June 1, 2008 Link to item Cite

Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL).

Journal Article J Clin Oncol · May 20, 2008 14588 Background: Vorinostat, a histone deacetylase inhibitor, was approved in 2006 by the FDA for the treatment of the cutaneous manifestations of CTCL in patients with progressive, persistent, or recurrent disease on or following 2 prior systemic therapi ... Link to item Cite

Non-Hodgkin's lymphomas.

Journal Article J Natl Compr Canc Netw · April 2008 Full text Link to item Cite

Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.

Journal Article J Natl Compr Canc Netw · April 2008 The NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Disease were recently revised to include recommendations for treating mycosis fungoides and Sézary syndrome. These uncommon lymphomas require a specialized evaluation and use a unique TNMB st ... Full text Link to item Cite

Keratosis follicularis spinulosa decalvans in a family.

Journal Article J Am Acad Dermatol · March 2008 Keratosis follicularis spinulosa decalvans (KFSD) is a rare condition characterized by diffuse keratosis pilaris with a scarring alopecia of the scalp and associated photophobia, facial erythema, and palmoplantar keratoderma. Although initially described a ... Full text Link to item Cite

Subcutaneous efalizumab is not effective in the treatment of alopecia areata.

Journal Article J Am Acad Dermatol · March 2008 BACKGROUND: Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis. OBJECTIVE: To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA. ... Full text Link to item Cite

Central scalp alopecia photographic scale in African American women.

Journal Article Dermatol Ther · 2008 Central centrifugal cicatricial alopecia (CCCA) is a common but poorly understood cause of hair loss in African American women. A photographic scale was developed that captures the pattern and severity of the central hair loss seen with CCCA in order to he ... Full text Link to item Cite

Central centrifugal cicatricial alopecia.

Journal Article Dermatol Ther · 2008 A progressive scarring alopecia of the central scalp is commonly seen in young to middle-aged females of African descent. It usually starts at the vertex or mid top of the scalp and gradually spreads centrifugally, hence, the unifying term of central centr ... Full text Link to item Cite

A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

Journal Article J Am Acad Dermatol · November 2007 BACKGROUND: An alternative to currently marketed topical minoxidil solutions is desirable. OBJECTIVE: To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA ... Full text Link to item Cite

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).

Journal Article Blood · September 15, 2007 The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques ... Full text Link to item Cite

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Journal Article J Clin Oncol · July 20, 2007 PURPOSE: To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes. ... Full text Link to item Cite

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).

Journal Article Blood · July 15, 2007 Currently availabel staging systems for non-Hodgkin lymphomas are not useful for clinical staging classification of most primary cutaneous lymphomas. The tumor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sézary syndrome (SS) is not a ... Full text Link to item Cite

The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.

Journal Article J Am Acad Dermatol · December 2006 BACKGROUND: Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor. OBJECTIVE: Our aim was to evaluate the efficacy of the type 1 and 2 5alpha-reductase inhibitor dutasteride in men ... Full text Link to item Cite

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.

Journal Article J Am Acad Dermatol · November 2006 BACKGROUND: Interleukin-12 (IL-12) increases Th(1) cytokines, natural killer (NK) cells, and cytotoxic T-cell activities. Progression of mycosis fungoides is associated with Th(2) cytokines produced by a clonal proliferation of epidermotropic T-helper cell ... Full text Link to item Cite

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Journal Article Blood · November 1, 2006 AbstractBackground: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally bioavailable. IV forodesine has shown clinical activity in patients with cutaneo ... Full text Cite

Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective.

Journal Article J Investig Dermatol Symp Proc · December 2005 Female pattern hair loss (FPHL) is a common hair disorder of the central scalp. The clinical change in hair density, related to a change in the hair cycle and miniaturization of the hair follicle, is generally considered to be potentially reversible. Howev ... Full text Link to item Cite

Defining early mycosis fungoides.

Journal Article J Am Acad Dermatol · December 2005 This editorial review summarizes the results of 5 meetings sponsored by the International Society for Cutaneous Lymphoma at which the clinicopathologic and ancillary features of early mycosis fungoides were critically examined. Based on this analysis, an a ... Full text Link to item Cite

Short anagen syndrome.

Journal Article J Am Acad Dermatol · August 2005 Short anagen syndrome is an uncommon, probably underreported, condition whose clinical characteristics are poorly recognized and whose incidence is poorly documented in the medical literature. We describe the clinicopathologic features of a child with shor ... Full text Link to item Cite

Alopecia areata investigational assessment guidelines-Part II

Journal Article Journal of the American Academy of Dermatology · September 1, 2004 Full text Cite

Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma.

Journal Article J Clin Oncol · July 15, 2004 6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells. Bcx-1777 is a small molecular weight inhibitor of purin ... Link to item Cite

Topical 5-fluorouracil is ineffective in the treatment of extensive alopecia areata.

Journal Article J Am Acad Dermatol · June 2004 We report the results of a pilot study of topical 5% 5-fluorouracil (FU) cream for the treatment of alopecia areata, an immunologically modulated disorder of hair growth. Patients with extensive (>50% scalp surface area involvement) alopecia areata that wa ... Full text Link to item Cite

Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.

Journal Article Hematol Oncol Clin North Am · December 2003 It is well accepted that cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, represent lymphomas that are highly responsive to immune modifying agents. Furthermore, the recent emphasis on the use of cytokine-related therapeu ... Full text Link to item Cite

Update on cicatricial alopecia.

Journal Article J Investig Dermatol Symp Proc · June 2003 Cicatricial alopecia is an enigmatic group of hair disorders linked by the potential permanent loss of scalp hair follicles in involved areas. Progress in our understanding and treatment of these disorders has been stymied by the lack of clear diagnostic c ... Full text Link to item Cite

Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss.

Journal Article Eur J Dermatol · 2003 A 24-month double-blind, randomized, placebo-controlled, parallel-group, multicenter study of 424 men was conducted to determine the efficacy and tolerability of finasteride 1 mg on hair growth/loss in men aged 41 to 60 years with mild-to-moderate, predomi ... Link to item Cite

Interferon in the treatment of cutaneous T-cell lymphoma.

Journal Article Dermatol Ther · 2003 Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete ... Full text Link to item Cite

Female pattern hair loss.

Journal Article J Am Acad Dermatol · November 2002 Full text Link to item Cite

Occupational alopecia or alopecia areata?

Journal Article J Am Acad Dermatol · October 2002 Full text Link to item Cite

A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.

Journal Article J Am Acad Dermatol · September 2002 BACKGROUND: Topical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in individuals with androgenetic alopecia (AGA). Results can be variable, and historical experience suggests that higher concentrations of topical minoxidi ... Full text Link to item Cite

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).

Journal Article Clin Lymphoma · March 2002 Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions. As part of a multicenter, randomized phase III trial in patients with heavily pretreated advanced and/or recurrent CTCL, the effects of an interleukin-2 recepto ... Full text Link to item Cite

Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.

Journal Article J Am Acad Dermatol · January 2002 Two conferences were sponsored by the International Society for Cutaneous Lymphomas (ISCL) to gain consensus on definitions and terminology for clinical use in erythrodermic cutaneous T-cell lymphoma (E-CTCL). Three subsets of E-CTCL were defined: Sézary s ... Full text Link to item Cite

Female pattern hair loss.

Journal Article J Am Acad Dermatol · September 2001 Full text Link to item Cite

The role for interleukin-12 therapy of cutaneous T cell lymphoma.

Journal Article Ann N Y Acad Sci · September 2001 Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressi ... Full text Link to item Cite

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma.

Journal Article J Am Acad Dermatol · June 2001 BACKGROUND: The purine nucleoside phosphorylase inhibitor peldesine is a new agent being evaluated as a T-cell inhibitor. OBJECTIVE: We attempted to determine the efficacy of peldesine (BCX-34) in a 1% dermal cream formulation as a treatment for cutaneous ... Full text Link to item Cite

Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

Journal Article Arch Dermatol · May 2001 OBJECTIVES: To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif). DESIGN: The effects of 2 randomized doses of 6.5 mg/m(2) per day (with crossover for progression) vs 650 mg/m(2 ... Link to item Cite

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Journal Article J Clin Oncol · January 15, 2001 PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CT ... Full text Link to item Cite

Female pattern hair loss: Clinical features and potential hormonal factors

Journal Article Journal of the American Academy of Dermatology · January 1, 2001 Full text Cite

Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.

Journal Article J Am Acad Dermatol · November 2000 BACKGROUND: Finasteride, an inhibitor of type 2 5alpha-reductase, decreases serum and scalp dihydrotestosterone (DHT) by inhibiting conversion of testosterone to DHT and has been shown to be effective in men with androgenetic alopecia (AGA). The effects of ... Full text Link to item Cite

The presence of loose anagen hairs obtained by hair pull in the normal population.

Journal Article J Investig Dermatol Symp Proc · December 1999 To help determine the specificity of "loose anagen" (LA) hairs in Loose Anagen Syndrome, the presence or absence of LA hairs on a gentle but firm hair pull was evaluated in 110 normal subjects from a 0.5 to 83 y old. In children < or =10 y old, 61% had LA ... Full text Link to item Cite

Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.

Journal Article J Am Acad Dermatol · October 1999 BACKGROUND: Androgenetic alopecia is a common condition of adult men. Finasteride, a type 2 5alpha-reductase inhibitor, decreases the formation of dihydrotestosterone from testosterone. OBJECTIVE: Two separate clinical studies were conducted to establish t ... Link to item Cite

Pityriasis amiantacea: a report of two cases in adults.

Journal Article Cutis · September 1999 Pityriasis amiantacea is a scaly condition of the scalp that is usually seen in children. It is most often associated with an underlying primary dermatosis. We describe two adult patients who did not present with concomitant scalp or cutaneous diseases. ... Link to item Cite

Methods of hair removal.

Journal Article J Am Acad Dermatol · February 1999 The methods of hair removal vary between simple inexpensive means of home treatment (shaving, plucking, depilatories) to expensive and potentially time-consuming means used by paraprofessionals, nurses, and/or physicians (electrolysis, lasers, x-ray). The ... Full text Link to item Cite

Hair removal in hirsutism

Journal Article Dermatologic Therapy · December 1, 1998 Patients with hirsutism can and do use physical means to remove terminal hair growth on the face, but medical assessment should be done prior to proceeding with expensive methods such as electrolysis or laser. Conditions such as hyperandrogenemia associate ... Cite

The diagnosis of androgenetic alopecia

Journal Article Dermatologic Therapy · December 1, 1998 Cite

Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.

Journal Article J Am Acad Dermatol · October 1998 BACKGROUND: Androgenetic alopecia (male pattern hair loss) is caused by androgen-dependent miniaturization of scalp hair follicles, with scalp dihydrotestosterone (DHT) implicated as a contributing cause. Finasteride, an inhibitor of type II 5alpha-reducta ... Full text Link to item Cite

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.

Journal Article Br J Dermatol · July 1998 This study compared the efficacy, safety and optimal dose of two formulations of cyclosporin, Sandimmun and Neoral, in patients with severe, chronic plaque-type psoriasis. Patients were randomized on a 1:1 basis to 24 weeks of treatment with Neoral (n = 15 ... Full text Link to item Cite

Sustained improvement in photodamaged skin with reduced tretinoin emollient cream treatment regimen: effect of once-weekly and three-times-weekly applications.

Journal Article J Am Acad Dermatol · August 1997 BACKGROUND: Previous studies have documented reversal of long-term photodamage with once-daily applications of topical tretinoin. OBJECTIVE: Our purpose was to assess the effectiveness of tretinoin emollient cream in maintaining improvement in photodamage ... Full text Link to item Cite

Tretinoin emollient cream for photodamaged skin: results of 48-week, multicenter, double-blind studies.

Journal Article J Am Acad Dermatol · August 1997 BACKGROUND: The ability of topical tretinoin to improve certain signs of skin photodamage has been shown previously. OBJECTIVE: Our purpose was to assess the effectiveness of tretinoin emollient cream in maintaining or further improving photodamaged skin d ... Full text Link to item Cite

Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.

Journal Article J Am Acad Dermatol · June 1997 BACKGROUND: The treatment of patients with advanced or therapy-refractory cutaneous T-cell lymphoma (CTCL) remains a challenge. Pentostatin is a potent inhibitor of adenosine deaminase and is selectively toxic to lymphocytes. In a small number of patients ... Full text Link to item Cite

Eccrine gland infiltration by mycosis fungoides.

Journal Article Am J Dermatopathol · October 1996 After identifying prominent eccrine infiltration by atypical lymphocytes in a biopsy of tumor stage mycosis fungoides (MF), we sought to determine the pattern of eccrine epithelial infiltration in MF. The frequency, intensity, and distribution of infiltrat ... Full text Link to item Cite

Histologic evaluation of the long term effects of tretinoin on photodamaged skin.

Journal Article J Dermatol Sci · March 1996 Sustained improvement with prolonged topical tretinoin for photodamaged skin has been well documented for up to 22 months of continuous treatment. We now report long-term (4 years) histologic effects of topical tretinoin in photodamaged skin of 27 patients ... Full text Link to item Cite

Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis.

Journal Article Cutis · February 1996 Two multicenter, double-blind, randomized, vehicle-controlled parallel-group trials involving 388 patients were conducted to compare the efficacy and safety of fluticasone propionate 0.005% ointment to those of its vehicle in the treatment of moderate-to-s ... Link to item Cite

Interferon in the treatment of cutaneous T-cell lymphoma.

Journal Article Hematol Oncol Clin North Am · October 1995 All of the recombinant interferons are active agents for the systemic treatment of mycosis fungoides and Sézary syndrome. The response rates are similar to those observed with systemic chemotherapy. There is no clear evidence that combining interferons wit ... Link to item Cite

Warning! Masoprocol is a potent sensitizer.

Journal Article J Am Acad Dermatol · August 1994 Full text Link to item Cite

Reply

Journal Article Journal of the American Academy of Dermatology · January 1, 1994 Full text Cite

Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease.

Journal Article Leukemia · June 1993 The recent characterization of the cutaneous lymphocyte-associated antigen (CLA) as a skin-selective homing receptor for skin-associated memory T cells has suggested a possible mechanism for the tropism demonstrated by the neoplastic T cells in cutaneous T ... Link to item Cite

Tretinoin emollient cream.

Journal Article J Am Acad Dermatol · February 1993 Full text Link to item Cite

Reply

Journal Article Journal of the American Academy of Dermatology · January 1, 1993 Full text Cite

Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata.

Journal Article Arch Dermatol · November 1992 BACKGROUND AND DESIGN: Thirty-two patients with mild to extensive alopecia areata, including 16 patients with alopecia totalis or universalis, entered a randomized, controlled trial of a 6-week taper of prednisone followed by either 2% topical minoxidil or ... Link to item Cite

Human test models for bioequivalence of topical corticosteroids: a review.

Journal Article Int J Dermatol · October 1992 It would be useful to have a safe, reliable, reproducible, and inexpensive human test model to determine the potency of topical corticosteroids and the bioequivalence of generic agents. Existing human test systems include erythema or inflammation induced b ... Full text Link to item Cite

Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis.

Journal Article J Am Acad Dermatol · August 1992 BACKGROUND: Despite extensive research on hyposensitization and prior application of topical barrier preparations, efforts to prevent Toxicodendron dermatitis have been only minimally successful. OBJECTIVE: Seven different barrier creams were evaluated for ... Full text Link to item Cite

Generalized papular xanthomatosis in mycosis fungoides.

Journal Article J Am Acad Dermatol · May 1992 Xanthomas can occur in association with underlying lymphoproliferative disease, or they can result from lipid deposition in damaged or altered skin. We report a case of generalized papular xanthomas that developed in a patient with Sézary syndrome. The xan ... Full text Link to item Cite

Tretinoin emollient cream: a new therapy for photodamaged skin.

Journal Article J Am Acad Dermatol · February 1992 BACKGROUND: Tretinoin administered topically in 0.1% concentration has been shown to improve the wrinkling and irregular pigmentation of photoaged skin. OBJECTIVE: The purpose of this study was to assess the safety and efficacy of various concentrations of ... Full text Link to item Cite

Comparison of oral fluconazole and topical clotrimazole in the treatment of fungal infections of the skin: European and American experience

Journal Article International Journal of Dermatology · January 1, 1992 An open, comparative, multicenter study conducted in Europe and the United States evaluated the efficacy and safety of oral fluconazole and topical clotrimazole in fungal infections of the skin. Patients were randomized to receive fluconazole, 50 mg per da ... Cite

Central nervous system involvement by cutaneous T cell lymphoma.

Journal Article J Am Acad Dermatol · September 1991 Central nervous system disease in cutaneous T cell lymphoma is uncommon and is usually not considered in standard therapeutic regimens. We report three patients who had cutaneous T cell lymphoma with involvement of the central nervous system and review the ... Full text Link to item Cite

Topical minoxidil in the treatment of androgenetic alopecia in women.

Journal Article Cutis · September 1991 Twenty-eight women with mild to moderate androgenetic alopecia were randomly assigned to apply either 2 percent topical minoxidil or placebo (vehicle) to their involved scalp areas twice daily. At the end of thirty-two weeks, there was a statistically sign ... Link to item Cite

The pharmacology of methotrexate.

Journal Article J Am Acad Dermatol · August 1991 Methotrexate is a useful antimetabolite for the treatment of both benign and malignant proliferative disorders. When the pharmacokinetics and potential toxicity of this drug are understood, treatment regimens can be tailored to the underlying kinetics of t ... Full text Link to item Cite

A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck.

Journal Article J Am Acad Dermatol · May 1991 This double-blind, vehicle-controlled, multicenter study evaluated the efficacy and safety of a new topical antineoplastic agent, masoprocol, in the treatment of actinic keratoses of the head and neck. Of the 113 patients who applied topical masoprocol twi ... Full text Link to item Cite

TENASCIN (HEXABRACHION) IS INCREASED IN LESIONAL PSORIATIC SKIN

Conference JOURNAL OF INVESTIGATIVE DERMATOLOGY · April 1, 1991 Link to item Cite

A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.

Journal Article J Am Acad Dermatol · March 1991 The efficacy and safety of clobetasol propionate 0.05% scalp application was evaluated in 378 patients with moderate to severe scalp psoriasis in a double-blind vehicle-controlled parallel group study. After 2 weeks of twice-daily applications, 81% receivi ... Full text Link to item Cite

A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay.

Journal Article Arch Dermatol · February 1991 Six generic formulations of five topical steroids were compared for bioequivalence with their trade-name counterparts using an in vivo vasoconstriction assay. Two of six generic formulations were found to show significantly less vasoconstriction than the r ... Link to item Cite

A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis.

Journal Article J Am Acad Dermatol · November 1990 We studied the effectiveness of clobetasol propionate ointment 0.05% in experimentally induced Rhus dermatitis. Clobetasol rapidly decreased the vesiculation at each treated site, although the effect was most prominent at the site to which clobetasol was a ... Full text Link to item Cite

Transdermal viprostol in the treatment of male pattern baldness.

Journal Article J Am Acad Dermatol · September 1990 Fifty-seven men were randomly assigned for treatment of androgenetic alopecia with viprostol, vehicle, or placebo twice daily for 24 weeks. Nonvellus hair growth was assessed subjectively by both patient and investigator and objectively through hair counts ... Full text Link to item Cite

Sweating in ectodermal dysplasia syndromes. A review.

Journal Article Arch Dermatol · August 1990 Ectodermal dysplasia syndromes are currently classified based on constellations of clinical features, a major one of which is the presence or absence of normal sweating. The evaluation of sweating in these disorders has not been performed in a standardized ... Link to item Cite

INTERFERON ALFA-2A IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

Conference JOURNAL OF INVESTIGATIVE DERMATOLOGY · April 1, 1990 Link to item Cite

Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil.

Journal Article J Am Acad Dermatol · April 1990 Thirty-one men with androgenetic alopecia completed 4 1/2 to 5 years of therapy with 2% and 3% topical minoxidil. Hair regrowth with topical minoxidil tended to peak at 1 year with a slow decline in regrowth over subsequent years. However, at 4 1/2 to 5 ye ... Full text Link to item Cite

Natural history of androgenetic alopecia.

Journal Article Clin Exp Dermatol · January 1990 Twenty-two men with patterns III-Va androgenetic alopecia were entered into a 10-month study aimed at establishing information on the natural progression of hair loss over a period of time typical of studies of hair growth promoters. The methodology employ ... Full text Link to item Cite

A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis.

Journal Article J Am Acad Dermatol · October 1989 Acitretin, the active metabolite of etretinate, has the clinical advantage of a much shorter terminal elimination half-life. We report the results of a double-blind, placebo-controlled trial of acitretin (Soriatane) in 15 patients with moderate to severe p ... Full text Link to item Cite

Alopecia: evaluation and management.

Journal Article Prim Care · September 1989 The patient presenting with hair loss may have a primary dermatologic disease, a genetically engineered process, an infectious disease, an underlying systemic illness, a drug reaction, or a psychological disorder. By first dividing the process into one of ... Link to item Cite

Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata.

Journal Article J Am Acad Dermatol · June 1989 This study evaluated the effectiveness of systemic interferon alfa-nl versus isotretinoin in the treatment of condylomata acuminata. Patients were randomly assigned interferon alfa-nl, 5 million units, subcutaneously daily for 2 weeks then twice weekly for ... Full text Link to item Cite

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.

Journal Article J Am Acad Dermatol · March 1989 Twenty-two patients with Stages Ia to IVa cutaneous T cell lymphoma were entered into a controlled trial of interferon alfa-2a (Roferon-A). Patients initially received either 3 million IU interferon alfa-2a, or their dosage was escalated to 36 million IU i ... Full text Link to item Cite

Topical methotrexate therapy for psoriasis.

Journal Article Arch Dermatol · February 1989 In vitro percutaneous penetration of methotrexate is enhanced with 1-dodecylazacycloheptan-2-one (laurocapram [Azone]). Laurocapram-containing methotrexate formulations provide effective local inhibition of epidermal DNA synthesis in the in vivo hairless m ... Link to item Cite

Reply

Journal Article Journal of the American Academy of Dermatology · January 1, 1989 Full text Cite

Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).

Journal Article J Am Acad Dermatol · October 1988 2'-Deoxycoformycin, a potent inhibitor of adenosine deaminase, was administered to three patients with cutaneous T cell lymphoma refractory to multiple treatment modalities. Patient 1, who received 5 mg/m2/day for 3 days at 35- to 71-day intervals, has ach ... Full text Link to item Cite

Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon).

Journal Article J Am Acad Dermatol · August 1988 Nine men with refractory condylomata acuminata were treated with intramuscular interferon alfa-n1 and the effect on their serum lipid levels was noted. Comparison of lipid panels before and after interferon revealed that all nine patients had an increase ( ... Full text Link to item Cite

Autosomal dominant multiple cylindromas associated with solitary lung cylindroma.

Journal Article J Am Acad Dermatol · August 1988 The occurrence of multiple cutaneous cylindromas constitutes an uncommon autosomal dominant cutaneous disorder whose associations usually are limited to other cutaneous tumors. We report here the first case of a patient with multiple cutaneous cylindromas, ... Full text Link to item Cite

Sinus histiocytosis with massive lymphadenopathy. Case report and review of a multisystemic disease with cutaneous infiltrates.

Journal Article J Am Acad Dermatol · June 1988 A report of a patient with the rare syndrome of sinus histiocytosis with massive lymphadenopathy is presented here. This patient is unusual in several respects, including his longevity after diagnosis, the presence of a benign monoclonal gammopathy, and th ... Full text Link to item Cite

Erosion of psoriatic plaques after chronic methotrexate administration.

Journal Article Int J Dermatol · 1988 A 43-year-old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate. This unusual cutaneous sign may be the first sign of methotrexate toxicity. ... Full text Link to item Cite

Topical minoxidil in male pattern baldness: effects of discontinuation of treatment.

Journal Article J Am Acad Dermatol · July 1987 Ten men with male pattern baldness who had been treated with 2% or 3% minoxidil for at least 4 months were evaluated for any changes in scalp hair growth on and off drug. Objective assessments by hair counts showed a mean doubling of nonvellus target scalp ... Full text Link to item Cite

Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness.

Journal Article J Am Acad Dermatol · May 1987 Nine healthy men with type IVa or Va male pattern baldness completed a 4-month single-blinded controlled pilot study designed to assess the effect of ultraviolet light (UVL) on topical minoxidil-induced hair growth. Subjects applied 2% topical minoxidil so ... Full text Link to item Cite

Long-term follow-up of men with male pattern baldness treated with topical minoxidil.

Journal Article J Am Acad Dermatol · March 1987 Forty-one men with male pattern baldness completed 132 study weeks (2 years 9 months) with topical minoxidil and had follow-up 1-inch target-area vertex scalp hair counts. Initially these men were treated with either twice-daily 2% topical minoxidil for 12 ... Full text Link to item Cite

Letterer-Siwe disease in an adult.

Journal Article Cutis · February 1987 Letterer-Siwe disease, a proliferative disorder of Langerhans' cells, usually affects children during the first year of life. A 67-year-old woman is described here whose initial manifestation was a characteristic skin eruption. The clinical, pathologic, an ... Link to item Cite

Reply

Journal Article Journal of the American Academy of Dermatology · January 1, 1987 Full text Cite

Reply

Journal Article Journal of the American Academy of Dermatology · January 1, 1987 Full text Cite

A falling out following minoxidil: telogen effluvium.

Journal Article J Am Acad Dermatol · January 1987 Full text Link to item Cite

Topical clobetasol-17-propionate: review of its clinical efficacy and safety.

Journal Article J Am Acad Dermatol · August 1986 Clobetasol-17-propionate, the most potent of currently available topical steroids as predicted by the vasoconstrictor assay, has just been approved in the United States. In psoriasis, it has proved significantly more effective than class II steroids and as ... Full text Link to item Cite

Dose-response study of topical minoxidil in male pattern baldness.

Journal Article J Am Acad Dermatol · July 1986 Eighty-nine healthy men with male pattern baldness completed a 6-month double-blind, placebo-controlled study of 0.01%, 0.1%, 1%, and 2% topical minoxidil. Subjects on 2% topical minoxidil had a statistically significant increase in mean total target area ... Full text Link to item Cite

INTERFERON ALFA-2A IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

Journal Article JOURNAL OF INVESTIGATIVE DERMATOLOGY · April 1, 1986 Link to item Cite

Reply

Journal Article Journal of the American Academy of Dermatology · January 1, 1986 Full text Cite

Clobetasol propionate versus fluocinonide creams in psoriasis and eczema

Journal Article International Journal of Dermatology · December 18, 1985 A double-blind, parallel comparison was made of the short-term efficacy and safety of three times daily regimens of 0.05% clobetasol propionate cream and 0.05% fluocinonide cream in 114 adolescent and adult patients with psoriasis and 113 with eczema. Afte ... Cite

Scalp comedones after topical minoxidil.

Journal Article J Am Acad Dermatol · December 1985 Full text Link to item Cite

Clobetasol propionate versus fluocinonide creams in psoriasis and eczema.

Journal Article Int J Dermatol · September 1985 A double-blind, parallel comparison was made of the short-term efficacy and safety of three times daily regimens of 0.05% clobetasol propionate cream and 0.05% fluocinonide cream in 114 adolescent and adult patients with psoriasis and 113 with eczema. Afte ... Full text Link to item Cite

Topical minoxidil in early male pattern baldness.

Journal Article J Am Acad Dermatol · August 1985 One-hundred twenty-six healthy men with early male pattern baldness completed a 12-month double-blind, controlled trial of 2% and 3% topical minoxidil. Subjects were initially randomly assigned to use placebo or 2% or 3% topical minoxidil. After 4 months o ... Full text Link to item Cite

HUMAN-LYMPHOBLASTOID ALPHA-INTERFERON IN THE TREATMENT OF REFRACTORY CONDYLOMA ACUMINATA

Journal Article JOURNAL OF INVESTIGATIVE DERMATOLOGY · January 1, 1985 Link to item Cite

Second malignancies in cutaneous T cell lymphoma.

Journal Article J Am Acad Dermatol · February 1984 Among sixty-three cutaneous T cell lymphoma (CTCL) patients seen over a 15-year period at the Duke University Medical Center (DUMC), 15.9% had a second malignancy. This is a higher frequency of second malignancies than has been documented previously in any ... Full text Link to item Cite

PARA-PSORIASIS EN PLAQUES - PHENOTYPIC ANALYSIS OF CUTANEOUS T-CELL INFILTRATES

Journal Article JOURNAL OF INVESTIGATIVE DERMATOLOGY · January 1, 1982 Link to item Cite